Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab in Relapsed/Refractory Advanced Mycosis Fungoides or Sezary Syndrome
NCT00057967Phase 2Completed
- Sponsor
- Northwestern University
- Start
- Jul 2000
- Primary completion
- Jun 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab in mycosis fungoides (MF) and Sézary syndrome (SS), sponsored by Northwestern University. Primary endpoints: Response Rate and Toxicity. Started Jul 2000; status: completed.
02
Drugs
alemtuzumab
03
Conditions
mycosis fungoides (MF)Sézary syndrome (SS)
Beyond the preview
Go deeper on NCT00057967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00057967.